Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease

Introduction: Chronic immune-mediated diseases, including inflammatory bowel disease (IBD), present an increased risk of developing early atherosclerosis and cardiovascular events (CVE) at early age. Objective: To describe the baseline and 1-year cardiovascular profile of patients with IBD according to the biologic treatment received, taking into account the inflammatory activity. Patients and methods: It is a retrospective, observational study that included 374 patients. Cardiovascular risk factors (CVRF) and CVE were collected at the baseline visit and at one-year follow-up to describe the cardiovascular risk according to the biological treatment received, also assessing clinical and biological remission. Results: A total of 374 patients were included: 146 (38.73%) were treated with Infliximab, 128 (33.95%) with adalimumab, 61 (16.18%) with ustekinumab and 42 (11.14%) with vedolizumab. The changes in blood glucose levels are [86.31 mg/dL (84.57-88.06) vs. 89.25 mg/dL (87.54-90.96), P=.001] for those treated with antiTNFct and [86.52 mg/dL (83.48-89.55) vs. 89.44 mg/dL (85.77-93.11), P=.11] in the other group. In the group treated with antiTNF alpha total cholesterol values at baseline visit are [169.40 mg/dL (164.97-173.83) vs. 177.40 mg/dL (172.75-182.05) at one year of treatment, P=<.001], those of HDL [50.22 mg/dL (48.39-52.04) vs. 54.26 mg/dL (52.46-56.07), P=<.001] and those of tri-glycerides [114.77 mg/dL (106.36-123.18) vs. 121.83 mg/dL (112.11--131.54), P=.054]. Regarding weight, an increase was observed, both in those patients treated with antiTNFct [71.39 kg (69.53-73.25) vs. 72.87 kg (71.05-74.70), P<.001], and in the group treated with ustekinumab and vedolizumab [67.59 kg (64.10-71.08) vs. 69.43 kg (65.65-73.04), P=.003]. Concerning CVE, no significant differences were observed neither according to the drug used (p = 0.36), nor according to personal history of CVE (P=.23) nor according to inflammatory activity (P=.46). Conclusions: Our results on a real cohort of patients with IBD treated with biologic drugs show a better control of certain cardiovascular parameters such as CRP or HDL, but a worsening of others such as total cholesterol or triglycerides, regardless of the treatment. Therefore, it is possibly the disease control and not the therapeutic target used, the one that affect the cardiovascular risk of these patients. (c) 2022 Elsevier Espana, S.L.U. All rights reserved.